SBL
SRPT icon

Sargent Bickham Lagudis’s Sarepta Therapeutics SRPT Stock Holding History

Sargent Bickham Lagudis’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-100
Closed -$17K – 978
2020
Q4 		$17K Hold
100
– – ﹤0.01% 580
2020
Q3 		$14K Buy
+100
New +$15.2K ﹤0.01% 554

Other funds holding SRPT

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Sargent Bickham Lagudis's SRPT Position: Q1 2021 in Review

Sargent Bickham Lagudis sold out of Sarepta Therapeutics (SRPT) in Q1 2021, closing a stake of 100 shares — an estimated $17K sold.

Sargent Bickham Lagudis first reported a position in SRPT in Q3 2020 and held it in 2 quarters. The position peaked at $17K in Q4 2020. 366 funds tracked by Wall St. Rank hold SRPT as of Q1 2021.

  • Sargent Bickham Lagudis reported no remaining Sarepta Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Sargent Bickham Lagudis sold 100 Sarepta Therapeutics shares in Q1 2021, an estimated $17K.
  • Sargent Bickham Lagudis first reported a position in Sarepta Therapeutics in Q3 2020 and held it in 2 quarters.
  • Sargent Bickham Lagudis's Sarepta Therapeutics position peaked at $17K in Q4 2020.
  • 366 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2021.

Based on Sargent Bickham Lagudis's 13F filing for Q1 2021, filed 24 May 2021.